Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters.
暂无分享,去创建一个
M. Hurme | J. Vilpo | L. Vilpo | M Hurme | J. Hulkkonen | L Vilpo | J Vilpo | J Hulkkonen | T Koski | T. Koski | Mikko Hurme | Juhani Vilpo
[1] S. Knuutila,et al. Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia , 1999, Leukemia.
[2] D. Catovsky,et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.
[3] M. Hurme,et al. Diminished production of interleukin‐6 in chronic lymphocytic leukaemia (B‐CLL) cells from patients at advanced stages of disease , 1998, British journal of haematology.
[4] G. Salles,et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. , 1998, Blood.
[5] C. Dinarello,et al. Biologic basis for interleukin-1 in disease. , 1996, Blood.
[6] H. Gralnick,et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. , 1989, Journal of clinical pathology.
[7] F. Pociot,et al. Monokine Antagonism Is Reduced in Patients With IDDM , 1994, Diabetes.
[8] J S Yudkin,et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.
[9] K. O. Elliston,et al. A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes , 1992, Nature.
[10] S. Knuutila,et al. Optimized mitogen stimulation induces proliferation of neoplastic B cells in chronic lymphocytic leukemia: significance for cytogenetic analysis , 1998, Cytogenetic and Genome Research.
[11] S. Nagata,et al. Involvement of an ICE-like protease in Fas-mediated apoptosis , 1995, Nature.
[12] O. Kallioniemi,et al. Frequent loss of the 11q14‐24 region in chronic lymphocytic leukemia: A study by comparative genomic hybridization , 1997, Genes, chromosomes & cancer.
[13] R. Płoski,et al. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism , 1995 .
[14] Robert Vlietinck,et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases , 1997, British journal of haematology.
[15] Pieter,et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. , 1995, Blood.
[16] M. Atkins,et al. Interleukin-6-associated anemia: determination of the underlying mechanism. , 1995, Blood.
[17] W. Fiers,et al. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis , 1995, Nature.
[18] K. Kliche,et al. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. , 1997, Blood.
[19] F. Pociot,et al. A Taql polymorphism in the human interleukin‐1β (IL‐1β) gene correlates with IL‐1β secretion in vitro , 1992 .
[20] R. Płoski,et al. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. , 1995, Arthritis and rheumatism.
[21] V. Praloran,et al. SERUM IL‐6 CONCENTRATIONS IN LYMPHOMAS , 1995, British journal of haematology.
[22] M. Hurme,et al. Non‐specific binding compromises the purification yields of leukemic B‐cells in chronic lymphocytic leukemia: prevention by collagen coating , 1998, European journal of haematology.
[23] M. Hallek,et al. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival , 1999, Journal of Molecular Medicine.
[24] M. James,et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.
[25] D. Colomer,et al. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. , 1997, Blood.
[26] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[27] A. Blakemore,et al. Single base polymorphism at −511 in the human interleukin-1β gene (IL1β) , 1992 .
[28] T J Hamblin,et al. Chronic lymphocytic leukaemia: the nature of the leukaemic cell. , 1997, Blood reviews.
[29] C. Gordon,et al. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. , 1994, Arthritis and rheumatism.
[30] I. Otterness,et al. Neutralization of endogenous IL-6 suppresses induction of IL-1 receptor antagonist. , 1995, Journal of immunology.
[31] A. Hoffbrand,et al. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. , 1996, Leukemia & lymphoma.
[32] M. Hurme,et al. Induction of beta-2-microglobulin release in vitro by chronic lymphocytic leukaemia cells: relation to total protein synthesis. , 1999, Leukemia research.
[33] G. Bagby. Interleukin-1 and hematopoiesis. , 1989, Blood reviews.
[34] M. Hurme,et al. IL‐1 receptor antagonist (IL‐1Ra) plasma levels are co‐ordinately regulated by both IL‐1Ra and IL‐1β genes , 1998 .